Commitment to a
Better You!
    Latisse - for Long Lovely Eye Lashes
Cosmetic Specialties

Discover the LATISSE® difference.

LATISSE® solution is a growth treatment for lashes. There’s been a growing
interest in this product ever since it was introduced. LATISSE® is the first FDA-
approved prescription treatment for inadequate or not enough eyelashes.
LATISSE® grows lashes longer, fuller and darker.  It’s not an illusion of growth. It’s
real eyelash growth!


How LATISSE® works.

LATISSE® makes lash growth possible because of its active ingredient bimatoprost.
LATISSE® solution is a once-nightly treatment that you will apply topically to the
base of your upper eyelashes. Then gradually you will see the results. You may
start to see more length in as little as 4 weeks and you should achieve full growth
in 16 weeks.


The history behind LATISSE®.

LATISSE® was created by Allergan, a pharmaceutical leader with 60 years of eye
care expertise. In 2001, Allergan developed a medicated eye drop to treat elevated
intraocular pressure. Many patients using this medication also began to grow
longer, fuller and darker lashes as a side effect. This led Allergan to study the
medication's active ingredient, bimatoprost, specifically for growing lashes. After a
clinical trial, LATISSE® was approved by the FDA in December of 2008.
LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information

Indication
LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat
hypotrichosis of the eyelashes by increasing their growth, including length,
thickness, and darkness.

Important Safety Information

Warnings and Precautions:
In patients using LUMIGAN®(bimatoprost ophthalmic
solution) or other prostaglandin analogs for the treatment of elevated intraocular
pressure (IOP), the concomitant use of LATISSE®may interfere with the desired
reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for
IOP reduction should only use LATISSE® after consulting with their physician and
should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when bimatoprost solution was
administered. Patients should be advised about the potential for increased brown
iris pigmentation, which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to
periorbital pigmented tissues and eyelashes. The pigmentation is expected to
increase as long as bimatoprost is administered, but has been reported to be
reversible upon discontinuation of bimatoprost in most patients.

There is the potential for hair growth to occur in areas where LATISSE®solution
comes in repeated contact with skin surfaces. Apply LATISSE®only to the skin of
the upper eyelid margin at the base of the eyelashes.

LATISSE® solution should be used with caution in patients with active intraocular
inflammation (eg, uveitis) because the inflammation may be exacerbated.

Adverse Reactions: The most frequently reported adverse events were eye
pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye
symptoms, and erythema of the eyelid. These events occurred in less than 4% of
patients.

Postmarketing Experience: The following reactions have been identified during
postmarketing use of LATISSE® in clinical practice: burning sensation (eyelid),
erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus,
iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis
(temporary loss of a few eyelashes to loss of sections of eyelashes, and
temporary eyelash breakage, respectively), rash (including macular,
erythematous, and pruritic limited to the eyelids and periorbital region), skin
discoloration (periorbital), and vision blurred.

Use in Specific Populations: Use in pediatric patients below the age of 16 years
is not recommended because of potential safety concerns related to increased
pigmentation following long-term chronic use.

Please see the full Prescribing Information.
___________________________________________________________________________________________________________________________
Medical Disclaimer
The information on this web-site or by any links to or from this site is strictly presented for educational purposes only.  
This information is not a recommendation for a specific treatment plan, product, or course of action or medical or healthcare
provider.  In addition, this information may become out of date over time.  It is important that you see a healthcare professional
for detailed information about medical conditions and treatments.  This information is not intended to be a substitute for the advice
of a healthcare professional or a recommendation for any particular treatment plan.
___________________________________________________________________________________________________________________________

Site Map     Disclaimer     Privacy Statement     Contact Us         Copyright 2007 Summit Surgical Institute, LLC.  All Rights Reserved.